Category: Debates & Comparisons
Ashwagandha is sold on cortisol numbers, rhodiola on burnout relief. The trials behind each measure different things, and a falling cortisol reading is not automatically the same as feeling less stressed. Here is the honest comparison.
Category: Debates and Comparisons | Reading time: ~12 min | Level: Intermediate
"Lowers cortisol" has become one of the most repeated phrases in supplement marketing, and ashwagandha wears it as its headline claim more than almost any other herb. Rhodiola gets a different pitch, less about a hormone number, more about burnout, exhaustion, the specific tiredness of running on empty for too long. Both claims sound like they are describing the same underlying problem: the physical toll of chronic stress. The trials behind them measured something more specific, and more complicated, than either marketing line suggests.
The honest starting point is this: a falling cortisol reading on a lab report and feeling less stressed are not automatically the same thing, and the research on ashwagandha itself has recently shown exactly that gap in stark terms. That does not make cortisol irrelevant, and it does not make either herb useless. It means the comparison worth having is not "which herb lowers cortisol more" but which herb has real evidence for the actual problem you have, biochemical or otherwise.
Ashwagandha (Withania somnifera) is a root from a shrub used for centuries in Ayurvedic medicine, generally standardised in modern extracts to a percentage of withanolides, its main group of active compounds. Its research programme has leaned heavily on measuring serum cortisol directly, alongside standard psychological stress questionnaires, in adults with self-reported chronic stress.
Rhodiola rosea is a root and rhizome from a cold-climate plant used traditionally across Scandinavia, Russia and Eastern Europe, standardised to rosavins and salidroside. Its research programme has leaned toward fatigue, burnout and mood outcomes rather than hormone measurement, with cortisol appearing mostly as a secondary, exploratory outcome rather than the trials' central focus.
Both are commonly grouped as adaptogens, a traditional pharmacology term for herbs proposed to help the body resist and recover from stress broadly. The proposed mechanism for both runs through the hypothalamic-pituitary-adrenal (HPA) axis, the hormonal chain that governs the stress response and ends in cortisol release, but "involves the HPA axis" is a mechanistic hypothesis, not a proven pathway, for either herb.
Ashwagandha's individual placebo-controlled trials on cortisol are more consistent than most herbal supplement evidence gets. A 2012 trial in 64 adults with a history of chronic stress gave 300mg of a high-concentration extract twice daily for 60 days and found serum cortisol fell by 27.9 percent in the treatment group against 7.9 percent in the placebo group, a statistically significant difference (P=0.0006), alongside significant improvements on every stress-assessment scale used [1]. A 2019 trial in 60 adults tested two doses, 125mg and 300mg twice daily, over eight weeks, and found significant cortisol reductions at both the lower dose (P<0.05) and the higher dose (P<0.0001), with the higher dose showing the larger effect, alongside improved Perceived Stress Scale scores and reported sleep quality [2].
Two consistent, well-conducted individual trials measuring the same direction of effect is a genuinely stronger evidence pattern than most single-ingredient claims in this space. Where the picture gets more complicated, and more honest, is at the meta-analysis level. A 2025 pooled analysis of 8 randomised controlled trials in 488 adults found ashwagandha significantly reduced cortisol levels overall, but found no significant improvement in perceived stress scores across the same body of trials [3]. That is a real and important dissociation: the biochemistry moved, the self-reported experience of stress, on average across the pooled evidence, did not move with it to a statistically significant degree.
A separate, larger 2025 meta-analysis of 15 studies in 873 people reached a more positive combined conclusion, reporting significant reductions in cortisol, Perceived Stress Scale scores and an anxiety scale (HAM-A) together [4]. The two meta-analyses used different sets of included trials and different statistical approaches, and their disagreement on whether the stress-scale improvement clears statistical significance is itself the honest state of this evidence: cortisol reduction is the most consistent single finding across the ashwagandha literature, the translation of that into a felt reduction in stress is real in some analyses and not in others.
NCCIH's own synthesis, sitting above the individual trials, calls the evidence for stress and sleep benefit "some preparations may help," language that reflects genuine but qualified support rather than settled proof, and separately notes the evidence for anxiety specifically is unclear [NCCIH]. Honest grade: moderate for stress, with the cortisol-lowering signal being the most consistently reproduced individual finding in the ashwagandha literature, and a real, unresolved question about whether that reliably translates into feeling less stressed.
Rhodiola's evidence looks very different once you go looking specifically for cortisol data, because there is barely any to find. Europe's herbal monograph grants rhodiola traditional use status for "the temporary relief of stress-related symptoms, such as fatigue and weakness," on the basis of long-standing use rather than a modern trial base, at daily doses of roughly 144 to 400mg [Rhodiola EMA].
The most relevant trial, a placebo-controlled study in 60 adults diagnosed with stress-related fatigue syndrome, measured the saliva cortisol awakening response, a narrower, secondary marker distinct from the daytime serum cortisol ashwagandha's trials measure, and found it changed differently in the treatment group compared with placebo over 28 days, alongside significant improvement on a validated burnout scale and several attention measures [Olsson 2009]. That is one small trial, using a different cortisol marker than the ashwagandha literature, as a secondary rather than primary outcome. A systematic review of the wider rhodiola-and-fatigue trial base described the overall evidence as contradictory [Ishaque 2012], and a separate randomised trial in nursing students working rotating shifts, a demanding real-world fatigue population, found rhodiola actually worsened self-reported fatigue compared with placebo over 42 days [Punja 2014].
Put plainly: rhodiola's case is built on fatigue and burnout outcomes, not cortisol, and even on those outcomes the evidence is genuinely mixed, with one credible positive trial and one credible negative one sitting in the same small literature. Honest grade: limited and heterogeneous for stress-related fatigue broadly, and essentially untested on cortisol specifically, which makes a head-to-head cortisol comparison with ashwagandha somewhat lopsided before it even starts.
| Feature | Ashwagandha | Rhodiola | |---|---|---| | Root part used | Root | Root and rhizome | | Active compounds | Withanolides | Rosavins, salidroside | | Primary trial outcome | Serum cortisol plus stress scales (PSS, DASS) | Fatigue, burnout and attention measures | | Direct cortisol evidence | Two individual RCTs, both significant reductions [1][2] | One small trial, secondary outcome (cortisol awakening response) [Olsson 2009] | | Meta-analytic verdict | Cortisol reduced consistently; effect on perceived stress disputed between analyses [3][4] | Not meta-analysed for cortisol; overall fatigue evidence called contradictory [Ishaque 2012] | | Evidence grade | Moderate for stress | Limited, heterogeneous | | Liver safety | LiverTox likelihood B, a likely cause of clinically apparent liver injury | No comparable liver signal in the literature reviewed | | Notable caution | Thyroid hormone effects; avoid in pregnancy, liver disease | Case reports of mania at high doses; avoid with bipolar vulnerability |
The comparison is lopsided in a specific, honest way. Ashwagandha has actually been tested against the outcome its marketing leads with. Rhodiola has not, and its genuine strength lies in a different outcome (fatigue and burnout) that its own marketing tends to undersell in favour of borrowing ashwagandha's cortisol language.
Start by asking what you are actually trying to fix, because "stress" covers several different problems and the evidence does not treat them interchangeably.
If your target genuinely is the biochemical marker, a documented, elevated cortisol pattern, or you simply want the herb with the more directly tested cortisol evidence, ashwagandha is the better-supported choice, with the honest caveat that a falling cortisol number is not a guarantee you will feel calmer, since the largest recent meta-analysis on that exact question found the two did not move together [3].
If your problem is closer to burnout, mental exhaustion, flat mood and poor concentration under sustained stress, rhodiola's specific trial evidence, thin and contradictory as it is, is a closer symptom match than ashwagandha's cortisol-centred literature, which has not specifically targeted burnout as an outcome.
Give either herb four to eight weeks, matching the trial durations behind them, before judging. Reframe "lowering cortisol" as a modest, structural goal (supporting how the body handles stress) rather than a guaranteed route to feeling less stressed, because the evidence itself does not support treating those as the same outcome. If your stress is severe, persistent, or affecting your ability to function, that is a conversation for a GP or therapist, not a supplement aisle decision.
The safety comparison matters as much as the efficacy one here, and the two herbs carry meaningfully different risks.
Ashwagandha's most serious documented signal is hepatic. NIH LiverTox rates it a likelihood B, a likely cause of clinically apparent liver injury in susceptible individuals, typically appearing 2 to 12 weeks after starting, usually presenting as a cholestatic or mixed pattern, mostly mild and resolving after stopping, though rare severe cases are on record. It should be avoided in cirrhosis or advanced liver disease. Ashwagandha also has documented effects on thyroid hormone levels, and NCCIH does not recommend it without medical supervision for people with thyroid disorders, autoimmune conditions, or hormone-sensitive prostate cancer, and advises stopping it before surgery. It should be avoided in pregnancy and not used while breastfeeding. Interaction cautions include thyroid medicines, sedatives, seizure medicines, immunosuppressants, and diabetes or blood pressure medicines [NCCIH].
Rhodiola's clinical trials generally report mild, transient side effects, but a small number of case reports describe mania in people taking high or excessive doses, particularly those with an underlying vulnerability to bipolar disorder, and it should not be combined with SSRIs, SNRIs or MAOIs without medical advice given its proposed action on serotonergic pathways. It is also advised against in pregnancy and breastfeeding.
Neither herb has the long-term safety data (beyond roughly three months of continuous use) to support open-ended, indefinite daily use without periodic review.
Pregnant, breastfeeding, or on medication? Check with a healthcare professional first.
We would rather tell you that "lowers cortisol" is a smaller, more contested claim than the marketing around ashwagandha usually admits, and that rhodiola's real strength lies somewhere the two herbs' reputations rarely separate: burnout-type exhaustion rather than a hormone panel. That is a less satisfying pitch than a single confident cortisol number, and it is the honest one.
If chronic, everyday stress with a plausible biochemical component is your problem, our ashwagandha stress tonic is formulated in that structure and function register: describing what the herb is shown to support in the body's response to stress, not promising a specific cortisol outcome or a cure for how you feel. If burnout and mental exhaustion are the dominant feature, treat that as a different problem, worth raising with the wider Remedy Library or with Remy, rather than reaching for the same cortisol-focused framing that fits ashwagandha's evidence better than rhodiola's.
1. Chandrasekhar K, Kapoor J, Anishetty S (2012). A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults. Indian Journal of Psychological Medicine, 34(3):255-62. PMID 23439798. n=64, 60 days; serum cortisol fell 27.9 percent versus 7.9 percent with placebo (P=0.0006). 2. Salve J, Pate S, Debnath K, Langade D (2019). Adaptogenic and anxiolytic effects of ashwagandha root extract in healthy adults: a double-blind, randomized, placebo-controlled clinical study. Cureus, 11(12):e6466. PMID 32021735. n=60, 8 weeks; significant cortisol reductions at 250mg/day and 600mg/day. 3. Albalawi AA (2025). Dual impact of ashwagandha: significant cortisol reduction but no effects on perceived stress, a systematic review and meta-analysis. Nutrition and Health. DOI 10.1177/02601060251363647. 8 RCTs, n=488; cortisol reduced significantly, Perceived Stress Scale scores not significantly improved. 4. Bachour G, Samir A, Haddad S, Houssaini MA, El Radad M (2025). Effects of ashwagandha supplements on cortisol, stress and anxiety levels in adults: a systematic review and meta-analysis. BJPsych Open. DOI 10.1192/bjo.2025.10136. 15 studies, n=873; significant reductions in cortisol, Perceived Stress Scale and HAM-A scores. 5. National Center for Complementary and Integrative Health (2026). Ashwagandha. Government evidence synthesis; stress and sleep evidence described as preliminary; anxiety evidence unclear; safety and interaction cautions. 6. NIH LiverTox (2026, last updated). Ashwagandha. NBK548536. Likelihood score B; latency 2 to 12 weeks; typically cholestatic or mixed, mostly mild and self-limiting; avoid in cirrhosis or advanced liver disease. 7. Ishaque S, Shamseer L, Bukutu C, Vohra S (2012). Rhodiola rosea for physical and mental fatigue: a systematic review. BMC Complementary and Alternative Medicine, 12:70. PMID 22643043. Concluded the trial evidence is contradictory. 8. Olsson EM, von Schéele B, Panossian AG (2009). A randomised, double-blind, placebo-controlled, parallel-group study of the standardised extract SHR-5 of the roots of Rhodiola rosea in the treatment of subjects with stress-related fatigue. Planta Medica, 75(2):105-12. PMID 19016404. n=60, 28 days; significant improvement on burnout and attention measures; secondary outcome of altered saliva cortisol awakening response versus placebo. 9. Punja S, Shamseer L, Olson K, Vohra S (2014). Rhodiola Rosea for mental and physical fatigue in nursing students: a randomized controlled trial. PLOS ONE, 9(9):e108416. PMID 25268730. Rhodiola worsened fatigue versus placebo over 42 days in shift-working nursing students. 10. European Medicines Agency, Committee on Herbal Medicinal Products (2024). European Union herbal monograph on Rhodiola rosea L., rhizoma et radix, Final Revision 1 (EMA/HMPC/24177/2023), adopted 20 March 2024. Traditional use status; dose 144 to 400mg daily.
Ashwagandha has the stronger, more direct evidence. Two separate placebo-controlled trials measured serum cortisol before and after treatment and found significant reductions, and newer meta-analyses confirm a pooled cortisol-lowering effect across multiple trials. Rhodiola has barely been tested on cortisol directly. Its best evidence measured a related but different marker, the cortisol awakening response, as a secondary outcome in a single small trial. If cortisol specifically is what you are trying to influence, ashwagandha has the better-supported case, though what a lower cortisol reading actually means for how you feel is a separate, more complicated question.
Ashwagandha's trials are built around a stress-hormone framing, measuring serum cortisol alongside standard stress questionnaires, mostly in people with chronic, self-reported stress. Rhodiola's trials lean toward a fatigue and burnout framing, measuring exhaustion, attention and mood rather than hormone levels, in people with diagnosed stress-related fatigue. Both are traditional adaptogens with overlapping folk reputations, but the modern research has pulled them in different directions: ashwagandha toward the biochemistry of stress, rhodiola toward its mental and physical exhaustion.
In the individual trials that measured it directly, yes, meaningfully. A 2012 trial found a 27.9 percent reduction in serum cortisol after 60 days of ashwagandha, against a 7.9 percent fall in the placebo group. A separate 2019 trial found significant cortisol reductions at two different doses. Pooled meta-analyses broadly confirm a cortisol-lowering effect. What is genuinely uncertain is whether that biochemical change reliably tracks with feeling less stressed: one 2025 meta-analysis of 8 trials found cortisol fell significantly while perceived stress scores did not improve significantly, a real and important disconnect.
It needs a real caution, not a dismissal. NIH LiverTox rates ashwagandha a likelihood B, meaning it is a likely cause of clinically apparent liver injury in susceptible individuals, typically appearing 2 to 12 weeks after starting, usually mild and self-limiting once stopped, though rare severe cases are documented. It should be avoided in cirrhosis or advanced liver disease, and anyone with existing liver concerns should discuss it with a clinician before starting, rather than treating it as risk-free because it is a traditional herb.
There is no dedicated trial evidence on the combination, and the two work through different, only partly understood mechanisms, so there is no clear pharmacological reason to avoid a sensible combined dose in someone with no contraindications to either. That said, layering two centrally active adaptogens increases the number of unknowns rather than decreasing them. If you want to trial an adaptogen for stress, start with one at a sensible dose, run it for several weeks, and only consider combining if you have a specific reason and no red-flag health conditions for either herb.
Not automatically, and this is one of the more important honest points in this comparison. Cortisol is a normal hormone the body needs, and a single blood or saliva measurement is a proxy for a complex system, not a direct readout of how stressed someone feels. A 2025 meta-analysis of ashwagandha trials found cortisol dropped significantly across the pooled trials while perceived stress scores did not improve significantly in the same body of evidence, a clear demonstration that the two do not always move together. Treat "lowers cortisol" as one data point about a supplement's biological activity, not as proof it will make you feel calmer.
Not without medical supervision. Ashwagandha has documented effects on thyroid hormone levels and NCCIH lists thyroid disorders among the conditions where it is not recommended without a doctor's involvement. If you have a diagnosed thyroid condition, particularly one already managed with medication, this is a conversation to have with the clinician managing it before starting ashwagandha, not a decision to make from a product label.
That profile leans toward rhodiola's evidence base rather than ashwagandha's. Rhodiola's most credible trial specifically recruited people diagnosed with stress-related fatigue syndrome and found improvement on burnout and attention measures. Ashwagandha's trials are generally in people with chronic, generalised stress rather than diagnosed burnout specifically. Neither is strongly evidenced, but if exhaustion is the dominant feature rather than tension or worry, rhodiola is the closer match, with the caveat that its overall evidence is more contradictory than ashwagandha's.
Not without checking with the clinician managing your thyroid medication first. Ashwagandha has documented effects on thyroid hormone levels, and combining it with thyroid medication without supervision risks destabilising a condition that is usually carefully dose-titrated. Rhodiola does not carry the same specific thyroid caution in the safety literature, which may make it the more straightforward option to discuss if you are choosing between the two with a thyroid condition in the picture.
Reframe the goal before picking a supplement. Cortisol is not inherently harmful, it is a hormone your body needs for a functioning stress response, and chasing a lower number on a lab test is not the same as addressing the actual sleep, workload or anxiety driving how you feel. The honest evidence, including a meta-analysis showing ashwagandha can lower measured cortisol without significantly improving how stressed people report feeling, suggests the biochemistry and the lived experience are not the same target. A herb described as supporting the body's response to stress is a reasonable, modest thing to trial; a herb marketed as a cortisol-lowering fix is overselling what the data shows.